SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cian Healthcare zooms on entering into agreement with CHI Pharmaceuticals, Nigeria

22 Aug 2023 Evaluate

Cian Healthcare is currently trading at Rs. 25.58, up by 1.68 points or 7.03% from its previous closing of Rs. 23.90 on the BSE.

The scrip opened at Rs. 23.80 and has touched a high and low of Rs. 25.58 and Rs. 23.80 respectively. So far 30000 shares were traded on the counter.

The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 41.10 on 31-May-2023 and a 52 week low of Rs. 13.55 on 22-Aug-2022.

Last one week high and low of the scrip stood at Rs. 25.58 and Rs. 22.10 respectively. The current market cap of the company is Rs. 63.94 crore.

The promoters holding in the company stood at 51.85%, while Non-Institutions held 48.15% stake in the company.

Cian Healthcare has entered into an Agreement with CHI Pharmaceuticals, Nigeria for manufacturing and supply of their products in the country of Nigeria, which is a great success of company to increase Export Business.

The company is excited to embark on this business venture, targeting the Nigerian Market, and taking on the manufacturing responsibilities for CHI Pharma's product range including Supramult, Supramult Plus, GYNOCARE, Spora-Derm, and CHIFENAC, they are shifting this business from korea to its facility in India.

Cian Healthcare is a WHO-GMP & ISO -9001:2015 certified transnational manufacturing Company with wide range of Pharmaceutical, Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness and Food supplement products.

Cian Healthcare Share Price

8.26 0.00 (0.00%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×